Understanding melanoma progression by gene expression signatures

Cancer Genomics: Molecular Classification, Prognosis and Response Prediction

Volumn 9789400758421, Issue , 2013, Pages 47-78

  Timar J ^a   Barbai, T ^a   Gyorffy, B ^a   Raso E ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84932620857     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-5842-1_2     Document Type: Chapter

References (67)

1. Balch CM, Soong S-J, Thompson JF (2004) The natural history of melanoma and factors predicting outcome. In: Thompson JF, Morton DL, Kroon BBR (eds) Textbook of melanoma. Taylor &Francis Group, London/New York, pp 181-199
2. Vidwans SJ, Flaherty KT, Fisher DE, Tenenbaum JM, Travers MD, Shrager J (2011) A melanoma molecular disease model. PLoS One 6(3):e18257. doi:10.1371/journal.pone. 0018257
3. Viros A, Fridlyand J, Bauer J, Lasithiotakis K, Garbe C, Pinkel D, Bastian BC (2008) Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 5(6):e120. doi:07-PLME-RA-2081 [pii] 10.1371/journal.pmed.0050120
4. Takata M, Murata H, Saida T (2009) Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res 23(1):64-71. doi:PCR645 [pii] 10.1111/j.1755-148X.2009.00645.x
5. Whiteman DC, Pavan WJ, Bastian BC (2011) The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment CellMelanoma Res 24(5):879-897. doi:10.1111/j.1755-148X.2011.00880.x
6. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Samuels Y (2011) Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43(5):442-446. doi:ng.810 [pii] 10.1038/ng.810
7. Haq R, Fisher DE (2011) Biology and clinical relevance of the micropthalmia family of transcription factors in human cancer. J Clin Oncol 29(25):3474-3482. doi:JCO.2010.32.6223 [pii] 10.1200/JCO.2010.32.6223
8. Mustika R, Budiyanto A, Nishigori C, Ichihashi M, Ueda M (2005) Decreased expression of Apaf-1 with progression of melanoma. Pigment Cell Res 18(1):59-62. doi:PCR205 [pii] 10.1111/j.1600-0749.2004.00205.x
9. Deli T, Varga N, Adam A, Kenessey I, Raso E, Puskas LG, Tovari J, Fodor J, Feher M, Szigeti GP, Csernoch L, Timar J (2007) Functional genomics of calcium channels in human melanoma cells. Int J Cancer 121(1):55-65. doi:10.1002/ijc.22621
10. Gyorffy B, Lage H (2007) A web-based data warehouse on gene expression in human malignant melanoma. J Invest Dermatol 127(2):394-399. doi:5700543 [pii] 10.1038/sj.jid.5700543
11. Cochran AJ, Bailly C, Paul E, Remotti F, Bhuta S (1997) Characteristics that relate to prognosis. In: Melanocytic tumors. Lippincott-Raven Publishers, Philadelphia
12. Manola J, Atkins M, Ibrahim J, Kirkwood J (2000) Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 18(22): 3782-3793
13. Streit M, Detmar M (2003) Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 22(20):3172-3179. doi:10.1038/sj.onc.1206457 1206457 [pii]
14. Dome B, HendrixMJ, Paku S, Tovari J, Timar J (2007) Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 170(1):1-15. doi:S0002-9440(10)60829-2 [pii] 10.2353/ajpath.2007.060302
15. Ladanyi A, Somlai B, Gilde K, Fejos Z, Gaudi I, Timar J (2004) T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma. Clin Cancer Res 10(2):521-530
16. Ladanyi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, Gaudi I, Timar J (2007) Density of DC-LAMP(C) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 56(9):1459-1469. doi:10.1007/s00262-007-0286-3
17. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ (2012) Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 13(1):e32-e42. doi:S1470-2045(11)70155-3 [pii] 10.1016/S1470-2045(11)70155-3
18. Ladanyi A, Timar J, Bocsi J, Tovari J, Lapis K (1995) Sex-dependent liver metastasis of human melanoma lines in SCID mice. Melanoma Res 5(2):83-86
19. Seiter S, Schadendorf D, Herrmann K, Schneider M, Rosel M, Arch R, Tilgen W, Zoller M (1996) Expression of CD44 variant isoforms in malignant melanoma. Clin Cancer Res 2(3):447-456
20. Dome B, Somlai B, Ladanyi A, Fazekas K, Zoller M, Timar J (2001) Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma. Virchows Arch 439(5):628-635
21. Girouard SD, Murphy GF (2011) Melanoma stem cells: not rare, but well done. Lab Invest 91(5):647-664. doi:labinvest201150 [pii] 10.1038/labinvest.2011.50
22. Dome B, Somlai B, Timar J (2000) The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. Anticancer Res 20(5C):3971-3974
23. Lee JH, Miele ME, Hicks DJ, Phillips KK, Trent JM, Weissman BE, Welch DR (1996) KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 88(23):1731-1737
24. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA (1990) Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 50(20):6757-6764
25. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, Martinka M, Li G (2003) Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 9(12):4409-4414
26. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, Brennan C, Hahn WC, Cordon-Cardo C, Wagner SN, Flotte TJ, Duncan LM, Granter SR, Chin L (2006) Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125(7):1269-1281. doi:S0092-8674(06)00718-5 [pii] 10.1016/j.cell.2006.06.008
27. Natali PG, Nicotra MR, Di Renzo MF, Prat M, Bigotti A, Cavaliere R, Comoglio PM (1993) Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer 68(4):746-750
28. Timar J, Raso E, Dome B, Ladanyi A, Banfalvi T, Gilde K, Raz A (2002) Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clin Exp Metastasis 19(3):225-232
29. Strizzi L, Hardy KM, Kirsammer GT, Gerami P, Hendrix MJ (2011) Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest 91(6):819-824. doi:labinvest201163 [pii] 10.1038/labinvest.2011.63
30. Timar J, Tovari J, Raso E, Meszaros L, Bereczky B, Lapis K (2005) Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology 69(3):185-201. doi:88069 [pii] 10.1159/000088069
31. Braeuer RR, Zigler M, Villares GJ, Dobroff AS, Bar-Eli M (2011) Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol 21(2):83-88. doi:S1044-579X(10)00126-4 [pii] 10.1016/j.semcancer.2010.12.007
32. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E,Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795):536-540. doi:10.1038/35020115
33. Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, Chiarion-Sileni V, Mocellin S, Rossi CR, Bicciato S, Wang E, Marincola FM, Zanovello P (2006) A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4:50. doi:1479-5876-4-50 [pii] 10.1186/1479-5876-4-50
34. Winnepenninckx V, Lazar V,Michiels S, Dessen P, StasM, Alonso SR, AvrilMF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98(7):472-482. doi:98/7/472 [pii] 10.1093/jnci/djj103
35. John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, Guilford PJ, Cebon JS (2008) Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 14(16):5173-5180. doi:14/16/5173 [pii] 10.1158/1078-0432.CCR-07-4170
36. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15(22):6939-6946. doi:1078-0432.CCR-09-1631 [pii] 10.1158/1078-0432.CCR-09-1631
37. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, Lonardi S, Zavadil J, Osman I, Bhardwaj N (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA 106(48):20429-20434. doi:0905139106 [pii] 10.1073/pnas.0905139106
38. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M, Lillehaug JR, Borg A, Lonning PE (2010) Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 16(13):3356-3367. doi:1078-0432.CCR-09-2509 [pii] 10.1158/1078-0432.CCR-09-2509
39. Scott KL, Nogueira C, Heffernan TP, van Doorn R, Dhakal S, Hanna JA, Min C, Jaskelioff M, Xiao Y, Wu CJ, Cameron LA, Perry SR, Zeid R, Feinberg T, Kim M, Vande Woude G, Granter SR, Bosenberg M, Chu GC, DePinho RA, Rimm DL, Chin L (2011) Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell 20(1):92-103. doi:S1535-6108(11)00195-4 [pii] 10.1016/j.ccr.2011.05.025
40. Lugassy C, Lazar V, Dessen P, van den Oord JJ, Winnepenninckx V, Spatz A, Bagot M, Bensussan A, Janin A, Eggermont AM, Barnhill RL (2011) Gene expression profiling of human angiotropic primary melanoma: selection of 15 differentially expressed genes potentially involved in extravascular migratory metastasis. Eur J Cancer 47(8):1267-1275. doi:S0959-8049(11)00033-5 [pii] 10.1016/j.ejca.2011.01.009
41. Schramm SJ, Mann GJ (2011) Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies.Mol Cancer Ther 10(8):1520-1528. doi:1535-7163.MCT-10-0901 [pii] 10.1158/1535-7163.MCT-10-0901
42. Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL (2009) Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 27(34):5772-5780. doi:JCO.2009.22.8239 [pii] 10.1200/JCO.2009.22.8239
43. Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101(7):452-474. doi:djp038 [pii] 10.1093/jnci/djp038
44. Schramm SJ, Campain AE, Scolyer RA, Yang YH, Mann GJ (2012) Review and crossvalidation of gene expression signatures and melanoma prognosis. J Invest Dermatol 132(2):274-283. doi:jid2011305 [pii] 10.1038/jid.2011.305
45. Becker B, Roesch A, Hafner C, Stolz W, Dugas M, Landthaler M, Vogt T (2004) Discrimination of melanocytic tumors by cDNA array hybridization of tissues prepared by laser pressure catapulting. J Invest Dermatol 122(2):361-368. doi:22240 [pii] 10.1046/j.0022-202X.2004.22240.x
46. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 102(17):6092-6097. doi:0501564102 [pii] 10.1073/pnas.0501564102
47. Jaeger J, Koczan D, Thiesen HJ, Ibrahim SM, Gross G, Spang R, Kunz M (2007) Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13(3):806-815. doi:13/3/806 [pii] 10.1158/1078-0432.CCR-06-1820
48. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S,Morris C, Xi Y, Howell P,Metge B, Samant RS, Shevde LA, LiW, Eschrich S, Daud A, Ju J,Matta J (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1:13. doi:1755-8794-1-13 [pii] 10.1186/1755-8794-1-13
49. Jewell R, Mitra A, Conway C, Iremonger J, Walker C, de Kort F, Cook M, Boon A, Speirs V, Newton-Bishop J (2011) Identification of differentially expressed genes in matched formalin-fixed paraffin-embedded primary and metastatic melanoma tumor pairs. Pigment Cell Melanoma Res. doi:10.1111/j.1755-148X.2011.00965.x
50. Timar J, Gyorffy B, Raso E (2010) Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis 27(6):371-387. doi:10.1007/s10585-010-9307-2
51. Gould Rothberg BE, Rimm DL (2011) Biomarkers: the useful and the not so useful-an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol 130(8):1971-1987. doi:jid2010149 [pii] 10.1038/jid.2010.149
52. Tawbi HA, Villaruz L, Tarhini A, Moschos S, Sulecki M, Viverette F, Shipe-Spotloe J, Radkowski R, Kirkwood JM (2011) Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. Br J Cancer 105(6):773-777. doi:bjc2011285 [pii] 10.1038/bjc.2011.285
53. Busch C, Geisler J, Lillehaug JR, Lonning PE (2010) MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. Eur J Cancer 46(11):2127-2133. doi:S0959-8049(10)00364-3 [pii] 10.1016/j.ejca.2010.04.023
54. Gallagher SJ, Thompson JF, Indsto J, Scurr LL, Lett M, Gao BF, Dunleavey R, Mann GJ, Kefford RF, Rizos H (2008) p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia 10(11):1231-1239
55. Jewell R, Conway C,Mitra A, Randerson-Moor J, Lobo S, Nsengimana J, Harland M,Marples M, Edward S, Cook M, Powell B, Boon A, de Kort F, Parker KA, Cree IA, Barrett JH, Knowles MA, Bishop DT, Newton-Bishop J (2010) Patterns of expression of DNA repair genes and relapse from melanoma. Clin Cancer Res 16(21):5211-5221. doi:1078-0432.CCR-10-1521 [pii] 10.1158/1078-0432.CCR-10-1521
56. Ascierto PA, Kirkwood JM (2008) Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 6:62. doi:1479-5876-6-62 [pii] 10.1186/1479-5876-6-62
57. Timar J, Meszaros L, Ladanyi A, Puskas LG, Raso E (2006) Melanoma genomics reveals signatures of sensitivity to bio-and targeted therapies. Cell Immunol 244(2):154-157. doi:S0008-8749(07)00061-5 [pii] 10.1016/j.cellimm.2006.12.009
58. Krepler C, Certa U, Wacheck V, Jansen B, Wolff K, Pehamberger H (2004) Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol 123(4):664-669. doi:10.1111/j.0022-202X.2004.23433.x JID23433 [pii]
59. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711-723. doi:NEJMoa1003466 [pii] 10.1056/NEJMoa1003466
60. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A,Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526. doi:10.1056/NEJMoa1104621
61. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809-819. doi:10.1056/NEJMoa1002011
62. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507-2516. doi:10.1056/NEJMoa1103782
63. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326):973-977. doi:nature09626 [pii] 10.1038/nature09626
64. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29(22):3085-3096. doi:JCO.2010.33.2312 [pii] 10.1200/JCO.2010.33.2312
65. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968-972. doi:nature09627 [pii] 10.1038/nature09627
66. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, Corless CL, Li L, Li H, Sheng X, Cui C, Chi Z, Li S, Han M, Mao L, Lin X, Du N, Zhang X, Li J, Wang B, Qin S (2011) Phase II, openlabel, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 29(21):2904-2909. doi:JCO.2010.33.9275 [pii] 10.1200/JCO.2010.33.9275
67. Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK (2011) KIT as a therapeutic target in metastatic melanoma. JAMA 305(22):2327-2334. doi:305/22/2327 [pii] 10.1001/jama.2011.746